GLP-1
Retatrutide: Complete 2026 Guide to the Triple Agonist GLP-1
Retatrutide is shaping up to be the most powerful weight-loss drug ever developed. With Phase 3 trial data showing nearly 29% mean body weight reduction — numbers that rival bariatric surgery — Eli Lilly's triple-agonist candidate has captured the attention of physicians, patients, and investors alike. But what exactly is